EluciDx is committed to advancing healthcare in low- and middle-income countries through policy advisory, capacity building, and targeted R&D — not as charity, but as a path to sustainable, commercially viable healthcare infrastructure.
Advisor
Advising the continental health agency of the African Union on pharmaceutical and diagnostics industry development strategy, policy frameworks, and building endogenous healthcare manufacturing capacity across the continent.
Strategy Advisor (Pro Bono)
Advising this World Bank-supported African Center of Excellence in Addis Ababa on advancing Ethiopian and African healthcare through human resource development programs, endogenous pharmaceutical and vaccine R&D capacity, and related government policy.
Principal Investigator on a rapid diagnostic test development program for visceral Leishmaniasis, funded by the RIGHT Foundation (2020–2025).
Licensed Phase 2-ready oral therapy for systemic fungal infections with global access provisions for developing countries, targeting Leishmaniasis in low-resource settings.
Published opinion on why monoclonal antibody viability in LMICs requires infrastructure investment (CDMOs) before product development. Advocates TSMC-style model.
“All efforts must be made to plan and establish a viable, self-sufficient healthcare infrastructure. The stubborn focus on 'getting things' to LMICs instead of fundamentally building up capability for LMICs to be independent, equal and ultimately more lucrative trading partners has meant that very little added value remained.”
— From “Regarding mAb access initiatives for LMICs” (2024)